Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 169

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 169
---
 beneficially owned, or over which control or direction is exercised, by the “related parties” of the Company who receive a “collateral benefit” in connection with the Arrangement. Each of Steve Forte, David Bonita, Thomas Civik, Samarth Kulkarni, Susan Molineaux, Ann D. Rhoads, Carol A. Schafer, Steven Stein, Sandra Alves, and BVF Partners L.P. is a “related party” of the Company (collectively, the “ Related Parties”). The accelerated vesting of Options and RSUs pursuant to the Plan of Arrangement, any termination and change of control benefits, and the indemnification and provision of insurance for the benefit of the directors and executive officers of the Company pursuant to the terms of the Agreement, all as described above under “ The Arrangement – Interests of the Company’s Directors and Executive Officers in the Arrangement,” may be considered “collateral benefits” received by the applicable directors or executive officers of the Company or its affiliates for the purposes of MI 61-101,subject to the availability of the exceptions described above. Following disclosure by each of the Related Parties of the number of securities of the Company held by them and the total consideration that they expect to receive pursuant to the Arrangement, the only Related Parties who are potentially receiving a “collateral benefit” in connection with the Arrangement and beneficially own or exercise control or direction over more than one percent (1%) of the Common Shares (taking into consideration Common Shares issuable upon the exercise of Options that are exercisable within a period of sixty (60) days following the Record Date) are Steve Forte and Michael Zinda. Based on the information set out in the table below and the expected value of the cash consideration to be received by Shareholders in connection with the Arrangement, currently estimated to be $1.82 per Common Share, subject to final determination prior to the Effective Time in accordance with the terms of the Agreement, the Transaction Committee has determined that the value of any benefits to be received by each of Steve Forte and Michael Zinda, net of any offsetting costs, is more than 5% of the value of consideration that Steve Forte and Michael Zinda, respectively, expect they will be beneficially entitled to receive under the terms of the Arrangement (including in exchange for the equity securities beneficially owned by them), based on the expected value of $1.82 per Common Share currently expected to be received by Shareholders in connection with